miDOT medication adherence app being used to engage Tuberculosis patients

BALTIMORE, MD. (October 21, 2014)

emocha has launched a pilot with the Baltimore City Health Department. The health department will use emocha’s medication adherence app, miDOT, to help tuberculosis (TB) patients adhere to their medication regimen while also fulfilling CDC-required Directly Observed Therapy (DOT).

The Acting Deputy Commissioner for Communicable Disease, Dr. Patrick Chaulk MD, PHD, says, “we believe that the miDOT app will increase the health department’s capacity to provide quality care for TB patients while freeing up clinician time for other critical TB control activities.”

DOT requires a clinician to physically observe a patient take their medication every day for at least six months. This is resource intensive, costly to the system, and burdensome for the patient. miDOT serves as a proxy for DOT. Patients use emocha’s HIPAA-compliant smartphone app, miDOT, to record themselves taking their medication at their own convenience. miDOT captures symptoms and securely submits the video to the emocha server, where a clinician can then observe and confirm adherence on the emocha web interface. miDOT improves the quality of care by allowing patients to self-manage their TB adherence to comply with DOT, and reduces the financial burden placed on health departments because of in-person DOT.

“One reason why emocha’s miDOT has gained so much traction nationally and internationally is simple: it solves a major problem,” says emocha CEO, Sebastian Seiguer. “Health departments continuously find themselves with fewer resources and, with miDOT, they can overcome resource constraints and give patients the care they need.”

About emocha Mobile Health

emocha empowers every patient to take every dose of medication through video technology and scalable human engagement. Patients use a smartphone application to video record themselves taking their medication. Providers or emocha Adherence Coaches use a secure web portal to assess adherence and engage with patients. The platform is being used by public health departments, clinical trials, hospitals, health centers, and managed care organizations to radically improve medication adherence for patients with tuberculosis, opioid use disorder, hepatitis C, diabetes, and other chronic and infectious diseases. Learn more at www.emocha.com.

National Institutes of Health Statement

Research reported in this publication was supported by the National Institute On Minority Health And Health Disparities of the National Institutes of Health under Award Number R43MD010521. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Contact: Michelle Mendes| email: mmendes@emocha.com | phone: 410.928.4016